Business & Consumer Services » Shell companies | Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
200.00
-
-
2,138.10
SG&A Expense
1,374.80
2,403.10
2,846.40
2,134.90
1,809.80
2,138.10
EBIT
1,374.80
2,403.10
2,646.40
2,134.90
1,809.80
2,138.10
Unusual Expense
-
363.10
205.80
-
-
-
Pretax Income
1,374.80
2,766.20
2,852.10
2,134.70
1,808.40
2,133.10
Consolidated Net Income
1,374.80
2,766.20
2,852.10
2,134.70
1,808.40
2,133.10
Net Income
1,374.80
2,766.20
2,852.10
2,134.70
1,808.40
2,133.10
Net Income After Extraordinaries
1,374.80
2,766.20
2,852.10
2,134.70
1,808.40
2,133.10
Net Income Available to Common
1,374.80
2,766.20
2,854.10
2,134.70
1,808.40
2,133.10
EPS (Basic)
0.03
0.06
0.06
0.04
0.03
0.04
Basic Shares Outstanding
41,583.10
44,405.60
46,793.50
47,875.80
55,817.50
58,796.10
EPS (Diluted)
0.03
0.06
0.06
0.04
0.03
0.04
Diluted Shares Outstanding
41,583.10
44,405.60
46,793.50
47,875.80
55,817.50
58,796.10
EBITDA
1,374.80
2,403.10
2,646.40
2,134.90
1,809.80
2,138.10
Non-Operating Interest Income
0.00
0.10
0.10
0.20
1.40
4.90
Preferred Dividends
-
-
2.00
-
-
-

About Lixte Biotechnology Holdings

View Profile
Address
248 Route 25A No. 2
East Setauket New York 11733
United States
Employees -
Website http://www.lixte.com
Updated 07/08/2019
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. It uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company was founded by John S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.